tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2023 Jan 30;2174779.
doi: 10.1080/22221751.2023.2174779. Online ahead of print.
Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: How many booster doses do we need?
Paskorn Sritipsukho M.D. M.Sc[SUP] 1 2 [/SUP], Thana Khawcharoenporn M.D. M.Sc[SUP] 1 3 [/SUP], Boonying Siribumrungwong M.D. Ph.D[SUP] 1 4 [/SUP], Pansachee Damronglerd M.D[SUP] 3 [/SUP], Nuntra Suwantarat M.D[SUP] 5 [/SUP], Araya Satdhabudha M.D[SUP] 2 [/SUP], Chanapai Chaiyakulsil M.D[SUP] 2 [/SUP], Phakatip Sinlapamongkolkul M.D[SUP] 2 [/SUP], Auchara Tangsathapornpong M.D[SUP] 2 [/SUP], Pornumpa Bunjoungmanee M.D[SUP] 2 [/SUP], Sira Nanthapisal M.D. Ph.D[SUP] 1 2 [/SUP], Chamnan Tanprasertkul M.D Ph.D[SUP] 1 6 [/SUP], Naiyana Sritipsukho Ph.D[SUP] 7 [/SUP], Chatchai Mingmalairak M.D[SUP] 4 [/SUP], Anucha Apisarnthanarak M.D[SUP] 1 3 [/SUP], Pichaya Tantiyavarong M.D. Ph.D[SUP] 8 [/SUP]
Affiliations
Abstract
The surge in coronavirus disease 2019 (COVID-19) caused by the Omicron variants of the severe acute respiratory syndrome coronavirus 2 necessitates researches to inform vaccine effectiveness (VE) and other preventive measures to halt the pandemic. A test-negative case-control study was conducted among adults (age ≥18 years) who were at-risk for COVID-19 and presented for nasopharyngeal real-time polymerase chain reaction testing during the Omicron variant-dominant period in Thailand (1 January 2022 to 15 June 2022). All participants were prospectively followed-up for COVID-19 development for 14 days after the enrollment. Vaccine effectiveness was estimated and adjusted for characteristics associated with COVID-19. Of the 7,971 included individuals, there were 3,104 cases and 4,867 controls. The adjusted VE among persons receiving 2-dose, 3-dose, and 4-dose vaccine regimens for preventing infection and preventing moderate-to-critical diseases were 33%, 48%, 62% and 60%, 74%, 76%, respectively. The VE were generally higher among those receiving the last dose of vaccine within 90 days compared to those receiving the last dose more than 90 days prior to the enrollment. The highest VE were observed in individuals receiving the 4-dose regimen, CoronaVac-CoronaVac-ChAdOx1 nCoV-19-BNT162b2 for both preventing infection (65%) and preventing moderate-to-critical diseases (82%). Our study demonstrated increased VE along with increase in number of vaccine doses received. Current vaccination programs should focus on reducing COVID-19 severity and mandate at least one booster dose. The heterologous boosters with viral vector and mRNA vaccines were highly effective and can be used in individuals who previously received the primary series of inactivated vaccine.
Keywords: COVID-19; Effectiveness; Omicron variant; Real-life; Thailand; Vaccine.
. 2023 Jan 30;2174779.
doi: 10.1080/22221751.2023.2174779. Online ahead of print.
Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: How many booster doses do we need?
Paskorn Sritipsukho M.D. M.Sc[SUP] 1 2 [/SUP], Thana Khawcharoenporn M.D. M.Sc[SUP] 1 3 [/SUP], Boonying Siribumrungwong M.D. Ph.D[SUP] 1 4 [/SUP], Pansachee Damronglerd M.D[SUP] 3 [/SUP], Nuntra Suwantarat M.D[SUP] 5 [/SUP], Araya Satdhabudha M.D[SUP] 2 [/SUP], Chanapai Chaiyakulsil M.D[SUP] 2 [/SUP], Phakatip Sinlapamongkolkul M.D[SUP] 2 [/SUP], Auchara Tangsathapornpong M.D[SUP] 2 [/SUP], Pornumpa Bunjoungmanee M.D[SUP] 2 [/SUP], Sira Nanthapisal M.D. Ph.D[SUP] 1 2 [/SUP], Chamnan Tanprasertkul M.D Ph.D[SUP] 1 6 [/SUP], Naiyana Sritipsukho Ph.D[SUP] 7 [/SUP], Chatchai Mingmalairak M.D[SUP] 4 [/SUP], Anucha Apisarnthanarak M.D[SUP] 1 3 [/SUP], Pichaya Tantiyavarong M.D. Ph.D[SUP] 8 [/SUP]
Affiliations
- PMID: 36715323
- DOI: 10.1080/22221751.2023.2174779
Abstract
The surge in coronavirus disease 2019 (COVID-19) caused by the Omicron variants of the severe acute respiratory syndrome coronavirus 2 necessitates researches to inform vaccine effectiveness (VE) and other preventive measures to halt the pandemic. A test-negative case-control study was conducted among adults (age ≥18 years) who were at-risk for COVID-19 and presented for nasopharyngeal real-time polymerase chain reaction testing during the Omicron variant-dominant period in Thailand (1 January 2022 to 15 June 2022). All participants were prospectively followed-up for COVID-19 development for 14 days after the enrollment. Vaccine effectiveness was estimated and adjusted for characteristics associated with COVID-19. Of the 7,971 included individuals, there were 3,104 cases and 4,867 controls. The adjusted VE among persons receiving 2-dose, 3-dose, and 4-dose vaccine regimens for preventing infection and preventing moderate-to-critical diseases were 33%, 48%, 62% and 60%, 74%, 76%, respectively. The VE were generally higher among those receiving the last dose of vaccine within 90 days compared to those receiving the last dose more than 90 days prior to the enrollment. The highest VE were observed in individuals receiving the 4-dose regimen, CoronaVac-CoronaVac-ChAdOx1 nCoV-19-BNT162b2 for both preventing infection (65%) and preventing moderate-to-critical diseases (82%). Our study demonstrated increased VE along with increase in number of vaccine doses received. Current vaccination programs should focus on reducing COVID-19 severity and mandate at least one booster dose. The heterologous boosters with viral vector and mRNA vaccines were highly effective and can be used in individuals who previously received the primary series of inactivated vaccine.
Keywords: COVID-19; Effectiveness; Omicron variant; Real-life; Thailand; Vaccine.